SBRT / SABR (stereotactische radiotherapie)
SBRT (stereotactische lichaamsbestraling) levert hoge bestralingsonderdelen in weinig fracties, met name bij oligometastasen, vroeg longcarcinoom en prostaatcarcinoom. De SABR-COMET-studie toonde overlevingsvoordeel bij oligometastatische ziekte. SBRT wordt steeds breder erkend als curatieve optie bij inoperabele tumoren.
20 artikelen
From Constraints to Confidence: A Roadmap of 'Simple' SBRT for Low-Resource Clinical Environments
Stereotactic body radiotherapie (SBRT) or SABR has revolutionized radiotherapie, building on the principles of rigid immobilization, image guidance, and accurate targeting.
Top 10 Tips for Stereotactic Body Radiotherapie Contouring and Planning in Oligogemetastaseerd Disease: Lessons Learned From the UK SBRT QA Program
Radiation therapy (RT) is a rapidly evolving field. Technology is continuously developing, with improved pretreatment and onboard imaging, more advanced treatment planning systems (TPS), increased acc
The State of Tomorrow’s SBRT
From Timmerman’s original “table on the wall”1 to HyTEC2, and whether you call it stereotactic ablative radiotherapie (SABR) or stereotactic body radiotherapie (SBRT), hypogefractioneerde stereotactic
SBRT in eerder bestraald gebied bij nodale oligorecidief prostaatcarcinoom: uitkomsten
Uitkomsten van stereotactische radiotherapie in eerder bestraalde gebieden bij nodale oligorecidief prostaatcarcinoom.
Stereotactic Ablative Radiotherapie for Oligoprogressive Gemetastaseerd RCC: Voorspellers of Prolonged Benefit from Ongoing Systemic Therapy
Stereotactic Ablative Radiotherapie (SABR) is increasingly employed to treat limited sites of oligoprogression in gemetastaseerd renal cell carcinoma during systemic therapy (ST).
Behandeling With Stereotactic Ablative Radiotherapie for Patiënten met up to 5 Oligogemetastaseerd Cancer Lesions: Langetermijn Uitkomsten of the Nongerandomiseerde Population-based Fase 2-SABR-5 Klinische trial
The use of SABR for oligogemetastaseerd cancer is expanding, but prospectieve langetermijn survival data are limited.
Renal SABR: Implementation of A New Standard of Care
SABR , or stereotactic ablative radiotherapie, has emerged as a new standard of care treatment option for localized renal cell carcinoma. Here, we present an accessible, high-yield guide to implementi
Local Control in Thoracic Stereotactic Ablative Radiotherapie: Analyse of Motion Management and Single-Fraction Dosimetry From the iSABR Trial
Thoracic stereotactic ablative radiotherapie (SABR) is an effective treatment for lung tumors.
A Studie of Curative-approach Behandeling Along With Metastasis-Directed Stereotactic Body Radiotherapie in Bone-Only Oligogemetastaseerd Borstkanker
A combination of metastasis-directed ablative therapy and curative-intent treatment for oligogemetastaseerd borstkanker is an active area of research.
Voorspellers of Langetermijn Disease-Free Survival With Stereotactic Body Radiotherapie for Oligogemetastaseerd Prostaatkanker
Stereotactic body radiotherapie (SBRT) is increasingly used for oligogemetastaseerd prostaatkanker, although most published series include mixed histologies and only a few patients achieve langetermij
Stereotactic Body Radiotherapie for Renal Tumors: A Prospectieve Fase 2-Klinische trial
Stereotactic body radiotherapie (SBRT) represents a novel, efficacious treatment for patiënten met kidney tumors who are medically inoperable or decline surgery.
Stereotactic Body Radiotherapie to the Prostate With Focal Boost: Analyse of the Primary Endpoint in the DELINEATE Trial Cohort E
Prostate stereotactic body radiotherapie (SBRT) is an effective approach for localized prostaatkanker.
Stereotactic Ablative Radiotherapie of Bone Metastases in an Oligogemetastaseerd Setting: One-Year Follow-Up of the BONY-M Fase 2-Trial
SABR is increasingly applied to treat oligogemetastaseerd disease (OMD). As patients may be asymptomatic, severe toxicity must be carefully balanced with effect in this setting.
Quality Assurance of Stereotactic Irradiation and Survival of Patiënten met Hoofd-hals Cancer in the A GORTEC 2014-04 “OMET” Gerandomiseerde Fase 2-Trial
The OMET GORTEC 2014-04 trial showed prolonged survival with multisite Stereotactic Ablative Body Radiation therapy (SABR) in patiënten met oligogemetastaseerd hoofd-hals cancer.
A Prospectieve Studie of Stereotactic Body Radiotherapie in Oligogemetastaseerd Renal Cell Carcinoma
Metastasis-directed therapy for oligogemetastaseerd renal cell carcinoma (RCC) with stereotactic body radiotherapie (SBRT) has been shown to improve progression-free survival (PFS) and delay time to s
Evaluating Toxicity and Interaction Uitkomsten of Systemic Therapy and Stereotactic Ablative Radiotherapie for Oligogemetastaseerd Disease: A Secondary Analyse of the Fase 2-SABR-5 Trial
Although stereotactic ablative radiotherapie (SABR) is known for low toxicity and safety, its combined use with specific systemic therapies requires further investigation.
Stereotactic Body Radiotherapie for Oligoprogressive Disease in Androgen-Suppressed Prostaatkanker: Primary Endpoint Analyse of the TRAP Trial
Optimal management of oligoprogressive prostaatkanker while on androgen receptor pathway inhibitors (ARPIs) is not known. The TRAP trial tests the role of stereotactic body radiotherapie (SBRT) in thi
A Fase 2-Trial of Radium223 and Stereotactic Ablative Radiotherapie in Hormone-Naïve Men with Oligogemetastaseerd Prostaatkanker to Bone: The RadSABR Studie
We hypothesized that treatment with Radium223 (Ra223) and Stereotactic ablative radiotherapy (SABR) in patiënten met bone-only metachronous oligometastastic hormone-sensitive prostaatkanker (moHSPC) c
SBRT plus abiraterone bij oligometastatisch prostaatcarcinoom
Fase II-studie naar een nieuwe behandelbenadering bij urologie. De studie onderzocht werkzaamheid en veiligheid als basis voor verdere klinische ontwikkeling.
SBRT met of zonder dismutasemimeticum bij pancreascarcinoom: fase II
Bestralingstudie naar radiotherapeutische behandelstrategieën bij gi tumoren met analyse van werkzaamheid en toxiciteit.